ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

Shares of ResMed Inc. RMD shed 1.16% to $211.49 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...

In a report released on April 10, Davinthra Thillainathan from Goldman Sachs maintained a Buy rating on Resmed Inc CHESS Depositary Interests ...

Mizuho analyst Anthony Petrone lowered the firm’s price target on ResMed (RMD) to $265 from $280 and keeps an Outperform rating on the shares ...

ResMed Inc. closed 18.65% short of its 52-week high of $263.05, which the company reached on January 30th.

ResMed shares have been caught up in the recent market volatility. Has this created a buying window for ResMed shares?

Australian healthcare stocks are navigating a challenging landscape from an onslaught of tariffs under the Trump administration, but Morgan Stanley has highlighted CSL and ResMed as the strongest ...

The Breas Z2 Auto is a good option for travelers who value simplicity. The machine comes with a bunch of accessories right in ...

SAN DIEGO – Resmed has announced that its home sleep apnea test, NightOwl, is now available across the U.S.